Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 4Head & Neck 3Genitourinary 2Lymphoid 1Dermatologic 1

Conditions

Prostatic Neoplasms 2Hot Flashes 2

Interventions

Docetaxel 229Radiotherapy 206Magnetic Resonance Spectroscopy 204Radiosurgery 176Gemcitabine 155pembrolizumab 150Nivolumab 147enzalutamide 140Prednisone 129Cisplatin 123Leuprolide 119Androgen Antagonists 117Abiraterone Acetate 114Sunitinib 106Specimen Handling 94Surveys and Questionnaires 91Goserelin 91bicalutamide 90Carboplatin 88Ipilimumab 82gallium 68 PSMA-11 80Blood Specimen Collection 78Everolimus 73apalutamide 72Radiation 71Standard of Care 68Biopsy 68acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 66Paclitaxel 64Cyclophosphamide 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Venlafaxine Hydrochloride × Genitourinary × Clear all
NCT00354432 2021-09-28

Soy Protein/Effexor Hormone Therapy for Prostate Cancer

Wake Forest University Health Sciences

Phase 3 Terminated
120 enrolled 11 charts
Genitourinary

Prostatic Neoplasms, Hot Flashes

NCT01533753 2019-11-21

Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer

University of Wisconsin, Madison

Phase 2 Terminated
5 enrolled 5 charts
Genitourinary

Prostatic Neoplasms, Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡